EA031331B9 - Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания - Google Patents

Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания

Info

Publication number
EA031331B9
EA031331B9 EA201400970A EA201400970A EA031331B9 EA 031331 B9 EA031331 B9 EA 031331B9 EA 201400970 A EA201400970 A EA 201400970A EA 201400970 A EA201400970 A EA 201400970A EA 031331 B9 EA031331 B9 EA 031331B9
Authority
EA
Eurasian Patent Office
Prior art keywords
lateral sclerosis
related disorder
amyotrophic lateral
acamprosate
riluzole
Prior art date
Application number
EA201400970A
Other languages
English (en)
Other versions
EA201400970A1 (ru
EA031331B1 (ru
Inventor
Даниель Коэн
Сергей Набирочкин
Илья Чумаков
Родольф Хадж
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/053565 external-priority patent/WO2012117073A2/en
Priority claimed from PCT/EP2012/053570 external-priority patent/WO2012117076A2/en
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201400970A1 publication Critical patent/EA201400970A1/ru
Publication of EA031331B1 publication Critical patent/EA031331B1/ru
Publication of EA031331B9 publication Critical patent/EA031331B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение имеет отношение к комбинациям и способам лечения амиотрофического бокового склероза (ALS) или родственного заболевания, такого как первичный латеральный склероз (PLS), прогрессирующая мышечная атрофия (PMA), псевдобульбарный синдром и прогрессирующий бульбарный синдром (PBP), а также лобно-височная деменция (FTD). Конкретнее, изобретение имеет отношение к новым комбинированным способам лечения амиотрофического бокового склероза или родственного заболевания.
EA201400970A 2012-03-01 2013-02-28 Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания EA031331B9 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2012/053565 WO2012117073A2 (en) 2011-03-01 2012-03-01 New compositions for treating neurological disorders
PCT/EP2012/053570 WO2012117076A2 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurogical disorders
PCT/EP2013/054024 WO2013127917A1 (en) 2011-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis
EP13706548.8A EP2819664B1 (en) 2012-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Publications (3)

Publication Number Publication Date
EA201400970A1 EA201400970A1 (ru) 2015-02-27
EA031331B1 EA031331B1 (ru) 2018-12-28
EA031331B9 true EA031331B9 (ru) 2019-02-28

Family

ID=47754536

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400970A EA031331B9 (ru) 2012-03-01 2013-02-28 Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания

Country Status (12)

Country Link
EP (3) EP3348261B1 (ru)
JP (1) JP6158234B2 (ru)
CY (1) CY1119195T1 (ru)
EA (1) EA031331B9 (ru)
HR (1) HRP20171206T1 (ru)
HU (1) HUE034212T2 (ru)
LT (1) LT2819664T (ru)
PL (1) PL2819664T3 (ru)
PT (1) PT2819664T (ru)
RS (1) RS56175B1 (ru)
SI (1) SI2819664T1 (ru)
UA (1) UA114811C2 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439626B2 (en) * 2019-09-20 2022-09-13 Icahn School Of Medicine At Mount Sinai Controlled release formulations of riluzole and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3180381B2 (ja) * 1991-08-31 2001-06-25 ウェルファイド株式会社 抗アルドステロン作用剤
WO2009133141A2 (en) * 2008-04-29 2009-11-05 Pharnext New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis
DK2282779T3 (da) * 2008-04-29 2013-05-27 Pharnext Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
CA2722295C (en) * 2008-04-29 2019-01-15 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2727588B1 (en) * 2011-03-01 2018-08-29 Pharnext Baclofen and acamprosate based therapy of neurological disorders
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level

Also Published As

Publication number Publication date
CY1119195T1 (el) 2018-02-14
LT2819664T (lt) 2017-10-25
JP6158234B2 (ja) 2017-07-05
PT2819664T (pt) 2017-08-24
SI2819664T1 (sl) 2017-12-29
HRP20171206T1 (hr) 2017-10-20
HUE034212T2 (en) 2018-02-28
EP3348261A1 (en) 2018-07-18
PL2819664T3 (pl) 2017-12-29
EA201400970A1 (ru) 2015-02-27
EP3235498A1 (en) 2017-10-25
UA114811C2 (uk) 2017-08-10
EA031331B1 (ru) 2018-12-28
EP2819664B1 (en) 2017-05-31
JP2015508797A (ja) 2015-03-23
EP3348261B1 (en) 2020-10-21
EP2819664A1 (en) 2015-01-07
RS56175B1 (sr) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
IN2015DN00438A (ru)
UA116981C2 (uk) Сполуки для лікування спінальної м'язової атрофії
MX368959B (es) Inhibidores heteroarilo de pde4.
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MX2014003767A (es) Procedimiento mejorado para la produccion de hematita finamente dividida y de pigmentos de oxido de hierro rojos.
MX2011007763A (es) Metodos y composiciones para tratamiento de cancer de pulmon.
EP3622073A4 (en) METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
NZ711587A (en) Substituted pyridine and pyrazine compounds as pde4 inhibitors
HK1214269A1 (zh) 肌萎縮側索硬化症 治療
IN2014CN04014A (ru)
MX361288B (es) Biocontrol de nematodos.
MX2019011542A (es) Metodo para la preparacion de oxido de grafeno a partir de grafito kish.
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX2012010084A (es) Compuestos utiles para tratar transtornos neurodegenerativos.
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
NZ702239A (en) Heteroaryl compounds and methods of use thereof
NZ729803A (en) A method for the treatment of motor neuron diseases
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
EA031331B9 (ru) Комбинация акампросата, баклофена и рилузола для лечения амиотрофического бокового склероза и родственного заболевания
EP2919816A4 (en) COMBINATION TREATMENT FOR AMYOTROPHE LATERAL SCLEROSIS (ALS)
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU